ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Q: When and where is the ORIC poster for enozertinib presented at ESMO Asia 2025?

The poster is scheduled for December 5, 2025, 5:15–6:15 p.m. SGT at the ESMO Asia Congress in Singapore.

Q: When is ORIC’s conference call/webcast for the ESMO Asia poster and is there a replay?

The conference call and live webcast is December 6, 2025 at 8:00 p.m. ET, and the webcast replay will be available for 90 days on the investor site.

Q: What is the session type and presentation number for ORIC’s enozertinib poster at ESMO Asia 2025?

It is a poster display session with Presentation Number 981P.

ORIC (Nasdaq: ORIC) will present clinical data for enozertinib (ORIC-114) in previously treated patients with HER2 exon 20 mutant NSCLC at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

ORIC (Nasdaq: ORIC) will present clinical data for enozertinib (ORIC-114) in previously treated patients with HER2 exon 20 mutant NSCLC at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).

The poster (Presentation 981P) is scheduled for Friday, December 5, 2025, 5:15–6:15 p.m. SGT in a poster display session.

ORIC will host a related conference call and live webcast on Saturday, December 6, 2025 at 8:00 p.m. ET; live Q&A will require pre‑registration and the webcast replay will be available via ORIC’s investor website for 90 days.

Argus Dec 1 session

-6.14% close to close Open Argus

Details

News Market Reaction – ORIC

On Dec 1, the day this news came out, ORIC closed 6.14% below the previous close.

Data tracked by StockTitan Argus for the Dec 1 session.

Key Figures

Conference dates: December 5–7, 2025 Conference call date: December 6, 2025 Conference call time: 8:00 pm ET +5 more

Conference dates: December 5–7, 2025; ESMO Asia Congress 2025 in Singapore
Conference call date: December 6, 2025; ORIC investor conference call and webcast
Conference call time: 8:00 pm ET; Scheduled time for the investor call
Trial phase: Phase 1b; Enozertinib (ORIC-114) HER2 exon 20 NSCLC trial
Poster number: 981P; ESMO Asia Congress 2025 poster identifier
Session date: December 5, 2025; Poster display session date
Session time: 5:15–6:15 p.m. SGT; Poster display session window
Webcast replay length: 90 days; Duration replay will be available on ORIC’s website

Historical Context

5 past events · Latest: Dec 05

5 events

Dec 05
Clinical data update

24h Move

-4.4%

Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity.
Dec 05
Equity inducement grants

24h Move

-4.4%

Inducement stock options and RSUs granted to new non-executive employees.
Dec 05
Clinical data update

24h Move

-3.5%

Phase 1b HER2 exon 20 NSCLC enozertinib data with 100% disease control at 80 mg.
Dec 04
Clinical data update

24h Move

+3.8%

ESMO data showing robust systemic and CNS activity in EGFR atypical mutations.
Dec 03
Conference presentation notice

24h Move

+3.1%

Announcement of late-breaking oral enozertinib presentations and investor call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1b, her2 exon 20, nsclc, her2 inhibitor, +1 more

5 terms

phase 1b medical

"poster presentation highlighting data from a Phase 1b trial of enozertinib"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

her2 exon 20 medical

"previously treated patients with HER2 exon 20 mutant NSCLC"

HER2 exon 20 is a specific segment (a single 'page') of the HER2 gene, which helps control how cells grow and divide. Mutations or changes in this segment can drive certain cancers and determine whether tumors respond to particular targeted drugs; for investors, that affects clinical trial success, drug approval odds, and the commercial value of therapies aimed at cancers with this genetic change.

nsclc medical

"patients with HER2 exon 20 mutant NSCLC"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

her2 inhibitor medical

"Brain Penetrant EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20"

A HER2 inhibitor is a drug or therapy that blocks the activity of the HER2 protein, which can drive rapid growth in certain cancers by acting like a stuck “on” switch on tumor cells. For investors it matters because successful HER2 inhibitors can change treatment standards, drive sales or licensing deals, and alter a company’s value based on clinical trial results, regulatory approvals, and competition—similar to how a single breakthrough product can transform a tech company’s prospects.

webcast technical

"host a conference call and webcast on Saturday, December 6, 2025"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

12/01/2025 - 08:00 AM

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.

Poster presentation details:

Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
	EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20
	Mutant NSCLC: Randomized Dose Optimization
Presentation Number:	981P
Session Type and Title:	Poster Display session and cocktail
Session Date & Time:	Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT

Full abstracts are available for public viewing via the ESMO Asia Congress website.

Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What data will ORIC (ORIC) present for enozertinib at ESMO Asia 2025?

A poster showing Phase 1b data for enozertinib in previously treated patients with HER2 exon 20 mutant NSCLC (Presentation 981P).

When and where is the ORIC poster for enozertinib presented at ESMO Asia 2025?

The poster is scheduled for December 5, 2025, 5:15–6:15 p.m. SGT at the ESMO Asia Congress in Singapore.

How can investors join ORIC’s conference call and webcast for the ESMO Asia presentation?

Pre‑register online to receive a phone number and passcode for the live call; a webcast and audio archive will be available on ORIC’s investor website.

When is ORIC’s conference call/webcast for the ESMO Asia poster and is there a replay?

The conference call and live webcast is December 6, 2025 at 8:00 p.m. ET, and the webcast replay will be available for 90 days on the investor site.

What is the session type and presentation number for ORIC’s enozertinib poster at ESMO Asia 2025?

It is a poster display session with Presentation Number 981P.

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025